Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating activities:
Net loss	$ (577,757)	$ (429,138)	$ (314,410)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	13,245	12,462	11,007
Non-cash operating lease cost	4,230	3,855	3,702
Non-cash interest expense and amortization of debt issuance costs	6,792	9,162	12,897
Scilex Notes principal increase		28,000
Payments on notes attributed to accreted interest related to the debt discounts	(22,973)	(13,172)
Stock-based compensation	74,847	90,188	31,419
Acquired in-process research and development	12,272	24,208	42,992
(Gain) loss on debt extinguishment, net	(27,009)	6,695	51,939
(Gain) loss on derivative liability	(7,316)	300	(6,600)
Loss on marketable and equity investments	83,919	15,013
Loss on equity method investments	18,426	126	5,844
Loss on impairment of intangible assets	124,190
(Gain) loss on contingent consideration	(75,400)	9,198
Non-cash inventory adjustments	10,962
Deferred income taxes	(1,836)	(35,927)	(2,125)
Changes in operating assets and liabilities, excluding effect of acquisitions:
Accounts receivable	(5,680)	(2,957)	(1,051)
Inventory	(9,510)	(6,276)	1,532
Accrued payroll	(13,442)	(111)	4,945
Prepaid expenses, deposits and other assets	6,803	(5,743)	4,913
Accounts payable	9,870	(3,878)	(3,677)
Accrued legal settlements	174,752
Accrued expenses and other liabilities	19,980	20,747	(1,188)
Deferred revenue	(112,300)	(1,024)	(362)
Other	(922)	(3,549)	(1,313)
Net cash used for operating activities	(293,857)	(281,821)	(159,536)
Investing activities:
Proceeds from sale of marketable investments		124,767
Purchases of property and equipment	(13,657)	(8,871)	(6,528)
Net cash provided by (used for) investing activities	(28,518)	79,847	(39,923)
Financing activities:
Proceeds from exercises of stock options and warrants	1,198	15,420	98,351
Proceeds from short-term debt, net of issuance costs	96,071	49,743	18,587
Repayments of debt and other obligations	(188,311)	(85,656)	(205,564)
Payments related to Semnur Share Exchange			(55,000)
Net cash provided by financing activities	311,718	181,332	174,239
Net change in cash, cash equivalents and restricted cash	(10,657)	(20,642)	(25,220)
Net effect of exchange rate changes on cash	(2,374)	843	915
Cash, cash equivalents and restricted cash at beginning of period	36,665	56,464	80,769
Cash, cash equivalents and restricted cash at end of period	23,634	36,665	56,464
Cash paid during the period for:
Income taxes	29	1,200
Interest	1,173	1,060	3,419
Supplemental disclosures of non-cash investing and financing activities:
Scilex Notes principal increase		28,000
ACEA acquisition consideration paid in equity		42,168
Right-of-use assets obtained in exchange for new and amended operating lease liabilities	5,592	49,459	1,878
Other acquisitions, license agreements and investments consideration paid in equity		13,689	9,544
Changes to noncontrolling interests from increased ownership in Scilex Holding		23,963
Deferred consideration for intangible asset acquisition	3,650
Short-term debt		7,304
Property and equipment costs incurred but not paid	6,790	1,253	600
Public Offering Of Common Stock And Warrants 2019
Financing activities:
Proceeds from issuance of common stock	402,334	201,825	317,865
SmartPharm
Supplemental disclosures of non-cash investing and financing activities:
Acquisition consideration paid in equity			19,421
Scilex Pharmaceuticals, Inc
Financing activities:
Proceeds from Business Combination	3,375
Transaction costs paid related to Business Combination	(2,949)
Supplemental disclosures of non-cash investing and financing activities:
Changes to noncontrolling interests related to Business Combination	1,998
Business Combination transaction costs incurred but not paid	7,001
Scilex Pharmaceuticals, Inc | Yorkville Purchase Agreement
Supplemental disclosures of non-cash investing and financing activities:
Shares issued pursuant to Purchase Agreement	1,237
Virex Health, Inc
Investing activities:
Acquisition consideration paid in cash, net of cash acquired	(6,544)
Supplemental disclosures of non-cash investing and financing activities:
Acquisition consideration paid in equity	4,434
ACEA Therapeutics, Inc
Investing activities:
Acquisition consideration paid in cash, net of cash acquired		(754)
Other Acquisitions and Investments
Investing activities:
Acquisition consideration paid in cash, net of cash acquired	$ (8,317)	$ (35,295)	$ (33,395)